Adynxx’s AYX1 injection wins US FDA fast track designation for chronic pain – Pharmaceutical Business Review

by admin on July 19, 2013

Adynxx's AYX1 injection wins US FDA fast track designation for chronic pain
Pharmaceutical Business Review
Clinical-stage pharmaceutical company Adynxx has obtained the US Food and Drug Administration (FDA) fast track designation for its AYX1 injection, which is used for prevention of chronic pain. In a five-cohort, dose-escalating study conducted in 30
Adynxx's AYX1 injection for prevention of chronic pain gets US FDA fast track pharmabiz.com

all 2 news articles »

View full post on chronic pain – Google News

Previous post:

Next post: